Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab for pulmonary cytokine storm in COVID-19
NCT05013034Phase 2Unknown
- Sponsor
- Fort Worth Clinical Sciences Working Group
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of basiliximab in coronavirus disease 2019 (COVID-19), cytokine storm (CRS), sponsored by Fort Worth Clinical Sciences Working Group. Status: unknown.
02
Drugs
basiliximab
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine storm (CRS)
Beyond the preview
Go deeper on NCT05013034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013034.